诊室内脉络膜上腔黏性固定术治疗急性孔源性视网膜脱离
这项在加拿大圣迈克尔医院开展的回顾性病例系列纳入6例原发性急性孔源性视网膜脱离患者,采用诊室内脉络膜上腔注射透明质酸钠(SCVEXY)联合激光视网膜固定术。5例(83.3%)实现解剖复位且无视网膜移位或外层视网膜褶皱,1例因视网膜裂孔后缘黏弹性物不足失败后行气性视网膜固定术成功。作者认为SCVEXY可能提供持久的视网膜复位,但需随机临床试验数据、更大样本量和更长期随访来评估其风险获益。
要点
- 6例原发性急性孔源性视网膜脱离患者接受诊室内SCVEXY,5例(83.3%)实现解剖复位且无视网膜移位或外层视网膜褶皱。
- 术后3个月平均logMAR视力为+0.46(SD 0.34),Snellen视力20/57。
- 1例SCVEXY失败因视网膜裂孔后缘黏弹性物不足,随后气性视网膜固定术成功;1例激光视网膜固定术后出现局限性脉络膜渗出,1周内消退。
核心结论
- 在这组6例病例系列中,SCVEXY的结果提示其可能为孔源性视网膜脱离提供持久的视网膜复位。
- 作者指出需要随机临床试验数据、更大样本量和更长期随访来评估SCVEXY与标准治疗相比的风险获益。
研究设计与样本
- 本研究为回顾性病例系列,于2023年6月至2024年2月在加拿大安大略省多伦多圣迈克尔医院开展。
- 连续纳入原发性急性孔源性视网膜脱离患者,其视网膜裂孔位于颞侧或鼻侧且可用当前诊室内SCVEXY技术触及。
- 暴露为在裂孔位置脉络膜上腔注射0.6 mL 2.3%透明质酸钠,使用30号针头及定制护套使针头露出1 mm;实现复位后围绕裂孔行激光视网膜固定术。
- 主要结局为SCVEXY的主要解剖复位率及功能和解剖完整性的恢复。
主要发现
- 6例患者中2例(33.3%)为女性,平均(SD)年龄52.5(19.7)岁。
- 每例患者最终随访时长分别为510、420、360、360、330和320天。
- 患者1至6的基线视力分别为手动、数指、20/100、20/100、20/25和手动。
- 术后所有病例均出现圆顶状脉络膜上腔扣带。
- 6例中5例(83.3%)实现解剖复位且无视网膜移位或外层视网膜褶皱,这些患者术后可立即恢复normal活动无限制。
局限性
- 原文指出需要随机临床试验数据、更大样本量和更长期随访来评估SCVEXY与标准治疗相比的风险获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In-office suprachoroidal viscopexy (SCVEXY) is a relatively new procedure for rhegmatogenous retinal detachment (RRD), but minimal information is available regarding outcomes and safety. OBJECTIVE: To report outcomes with in-office SCVEXY for primary acute RRD. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series was conducted at St Michael's Hospital in Toronto, Ontario, Canada from June 2023 to February 2024 among consecutive patients with primary acute RRDs who presented with retinal tears that were reachable with the current in-office SCVEXY technique in the temporal or nasal retina. EXPOSURE: Suprachoroidal injection of 0.6 mL of sodium hyaluronate, 2.3%, at the break location using a 30-gauge needle with a custom-made guard leaving 1 mm of the needle exposed. Laser retinopexy was applied around the break once reattachment was achieved. MAIN OUTCOME AND MEASURES: The primary outcome was primary anatomic reattachment rate with SCVEXY and recovery of function and anatomic integrity. RESULTS: Among 6 patients, 2 patients (33.3%) were female, and mean (SD) patient age was 52.5 (19.7) years. The final follow-up duration for each patient was 510, 420, 360, 360, 330, and 320 days, respectively. Baseline VAs were hand motions, counting fingers, 20/100, 20/100, 20/25, and hand motions for patients 1 through 6, respectively. A dome-shaped suprachoroidal buckle was present in all cases after the procedure. Five of 6 patients (83.3%) achieved anatomic reattachment with no retinal displacement or outer retinal folds, and these patients could resume normal activity immediately after the procedure with no restrictions. The mean (SD) logMAR VA at 3 months was +0.46 (0.34) (Snellen 20/57). The viscoelastic persisted in the suprachoroidal space as confirmed by multimodal imaging for 10, 14, 21, 13, 24, and 14 days, respectively, and the retina remained attached during the entire postoperative follow-up period. One patient's SCVEXY failed due to inadequate viscoelastic at the posterior edge of the retinal break, and this patient underwent a successful pneumatic retinopexy. One patient developed a localized choroidal effusion unrelated to the SCVEXY site following laser retinopexy that resolved in 1 week associated with topical prednisolone, 1%, 4 times daily and cyclopentolate, 1%, twice daily. CONCLUSIONS AND RELEVANCE: In this case series, the outcomes of these 6 cases suggest that SCVEXY may offer durable retinal reattachment in RRD. However, randomized clinical trial data, larger sample sizes, and longer-term follow-up are necessary to assess the risk-benefit profile of SCVEXY compared with the standard of care.
引用
- Muni RH, Melo IM, Demian S, et al. In-Office Suprachoroidal Viscopexy for Acute Rhegmatogenous Retinal Detachment. JAMA Ophthalmol. 2025. PMID: 39666366. doi:10.1001/jamaophthalmol.2024.5202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。